S2Medical AB (publ) has received the notice that Israeli authorities intend to grant patent approval for the company's instagraft technology in Israel. The instagraft technology is a surgical instrument that can be used for minimally invasive skin transplantation and is intended to move this procedure from specialist units out to the primary healthcare units. This would result in a higher number of patients suffering from chronic ulcers getting access to skin transplantation and thereby being able to heal their wounds.